Divya Chari, M.D.
Meet the Researcher
Chari received her medical degree from the Columbia University Vagelos College of Physicians and Surgeons. She is an investigator in the Jenks Vestibular Diagnostic and Physiology Laboratories at Mass Eye and Ear and a lecturer of otolaryngology–head and neck surgery at Harvard Medical School, and holds a clinical appointment at UMass Memorial Medical Center. Chari’s 2024 Emerging Research Grant was generously funded by an anonymous donor, and it was renewed for a second year in 2025, generously funded by Karen I. Coley.
Research on Ménière’s disease (MD) has been hampered because the “disease” encompasses a wide range of heterogeneous disorders that share the symptoms of a fluctuating, progressive, sensorineural hearing loss and periodic vertigo. In addition, there is no established animal model of MD and treatment is imprecise and aimed at mitigating symptoms rather than reversing the disease.
The genesis for this project arose through a collaboration with Andreas Eckhard, M.D., a co-investigator on the grant. Using postmortem human temporal bone specimens and in vivo radiologic studies, Dr. Eckhard and team demonstrated that MD patients could be classified into distinct subtypes. One subtype, MDhp, demonstrated an incompletely developed (hypoplastic) endolymphatic sac and vestibular aqueduct and had a high prevalence of X-linked hypophosphatemia. (XLH).
XLH is a genetic phosphate metabolism and bone growth disorder caused by a loss-of-function variant in the Phex gene. Our preliminary studies suggest that the Phex gene- deficient XLH mouse shares features with the MDhp cohort: hearing loss and balance dysfunction, endolymphatic hydrops, and hypoplasia of the endolymphatic sac and vestibular aqueduct. Our aim is to show that the Phex gene-deficient mouse can be a reliable animal model for the MDhp subtype, with an overall goal of developing gene diagnostics for MD and potential treatment options, such as gene therapy, to halt its progression.
As an undergrad at Yale, I enrolled in an introductory molecular biochemistry course. The guest professor was Joan Steitz, Ph.D., a leading scientist in the field. Dr. Steitz is best known for her pioneering work in RNA. Her enthusiasm for the course material was contagious and inspired me to pursue a path of scientific discovery. Her mentorship was also invaluable, and now mentoring students myself is an especially rewarding part of my career.
I am currently a practicing surgeon-scientist with a clinical appointment as an otologist/neurotologist and a principal investigator of a translational laboratory on MD. I medically and surgically treat patients with hearing and balance problems, including MD. Informed by my patients, I want to improve diagnostics and outcomes in otologic disorders.
I like to spend time outdoors with my family—my husband, our two children, and our dog Frankie. We love to hike and bike in the summer and ski in the winter. I also play classical violin, a childhood passion. Much of my early research endeavors relied on my music knowledge as I studied music and complex sound perception in cochlear implant users, and I still find that some of my best research ideas come after relaxing with music.
Divya Chari, M.D., is generously funded by an anonymous donor. HHF sincerely thanks our community for supporting these projects that address the full range of hearing and balance science.
Click to download a PDF this Meet the Researcher profile.
The Research
Mass Eye and Ear
Auditory and vestibular phenotype characterization of a Ménière’s disease model in humans and mice with X-linked hypophosphatemia
Our group has begun to segregate the pool of Ménière’s disease patients into distinct subtypes based upon specific clinical characteristics and morphologic features of the inner ear endolymphatic sac and vestibular aqueduct. One cohort—designated MDhp—demonstrated on histopathology and radiologic imaging an incompletely developed (hypoplastic) endolymphatic sac and vestibular aqueduct and had a high comorbid prevalence of X-linked hypophosphatemia. XLH is a genetic phosphate metabolism and bone growth disorder caused by a loss-of-function variant in the Phex gene. The high coincidence of XLH in the MDhp cohort led to the hypothesis that the two disorders may have etiologic similarities. Our preliminary studies suggest that the Phex gene-deficient XLH mouse also recapitulates clinical features of the MDhp cohort: hearing loss and balance dysfunction, endolymphatic hydrops, and hypoplasia of the endolymphatic sac and vestibular aqueduct. During this project we will determine whether the inner ear phenotype of humans with XLH generally resembles that of MDhp, and whether the XLH mouse model also exhibits an MDhp phenotype. Characterizing the MDhp phenotype within the context of patients with XLH and a Phex-deficient mouse model is a critical first step toward investigating the pathophysiology of MD and elucidating the genetic etiology of the MDhp subgroup. This research may demonstrate that the Phex gene-deficient mouse can be used as a reliable animal model of the MDhp subtype, which will pave the way for future studies of the role of the Phex gene mutation in MD patients and, more generally, the genetic basis of this complex disease.
Long-term goal: To open new avenues to the development of clinical, radiologic, and histopathologic biomarkers for the diagnosis of MD. In addition, the establishment of an animal model for this subtype of MD may herald rigorous studies investigating the underlying genetic etiology and pathophysiology of MD and may provide clues to the etiologies of other MD subtypes. We want to eventually develop the field of gene diagnostics for MD. Identification of specific gene loci associated with MD may lead to potential treatment options, such as gene therapy, to halt the progression of MD.